European Urology

Papers
(The H4-Index of European Urology is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)
ArticleCitations
Reply to Brett Delahunt, Hemamali Samaratunga, Lars Egevad’s Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Eviden823
Reply to Francesco Montorsi, Nicola Fossati, Carlo A. Bravi, Giorgio Gandaglia, Nazareno Suardi, and Alberto Briganti’s Letter to the Editor re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al819
Re: European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Cor471
Acknowledgement to Reviewers344
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer323
Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001293
Aberrant Splice Variants: A Novel Characterization of Clear Cell Renal Cell Carcinoma242
Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer231
Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu’s Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statisti213
The Platinum Hall of Fame205
Ischemia Time Has Little Influence on Renal Function Following Partial Nephrectomy: Is It Time for Urology to Stop the Tick-Tock Dance?192
Reply to Rui-Cheng Wu, Deng-Xiong Li, and De-Chao Feng’s Letter to the Editor re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Mo178
Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program158
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. 2024;8156
Opening up the Market to New Robotic Platforms: The Best Way To Handle New Options146
Congress Calendar138
Editorial Board137
Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via P133
Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions127
Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive C126
Reply to Xiangyang Yao, Chen Duan, Bo Li, Xiaoliang Wu and Hua Xu’s Letter to the Editor Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific 122
Editorial Board119
Congress Calendar116
Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi’s Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both t115
The Platinum Hall of Fame111
Reply to Feng Qi, Zicheng Xu, and Qing Zou’s Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-res107
Editorial Board102
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis100
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial100
Re: Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma94
Honing Stratification and Treatment for High-risk Prostate Cancer90
Radiopharmaceuticals in Genitourinary Cancers: A Fast-evolving Field with a Bright Perspective87
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types85
Oncological Benefits of Extended Pelvic Lymph Node Dissection: More Fog or Clarity to the Debate?85
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution84
Congress Calendar83
Editorial Board83
Contents83
Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries82
Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer80
Contents79
Contents78
Reply to Marc Furrer, Niranjan J. Sathianathen, and Nathan Lawrentschuk’s Letter to the Editor re: Pietro Piazza, Luca Sarchi, Stefano Puliatti, Carlo Andrea Bravi, Sophie Knipper, Alexandre Mottrie. 76
Application of deep learning convolutional neural network in prediction of stone location, skin to stone distance and composition in renal lithiasis: A single center pilot study76
VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prosta72
Re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association72
Editorial Board70
Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. 70
Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern70
Re: Unplanned Conversion from Partial to Radical Nephrectomy: An Analysis of Incidence, Etiology, and Risk Factors69
Is Office-based Management of Intermediate-risk Low-grade Non–muscle-invasive Bladder Cancer Ready For Prime Time?69
Platinum Hall of Fame69
Re: Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction68
Re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48–5468
Putting Precision Medicine in Prostate Cancer into Practice: Are We There Yet?67
Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Surgery: All Is in the Eye of the Beholder66
Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin’s Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate C66
Reply to Kunlin Yang, Xuesong Li, and Liqun Zhou’s Letter to the Editor re: Eduard Roussel, Giovanni Tasso, Riccardo Campi, et al. Surgical Management and Outcomes of Renal Tumors Arising from Horsesh65
Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer64
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma64
Re: Surgical Treatment for Recurrent Bulbar Urethral Stricture: A Randomised Open-label Superiority Trial of Open Urethroplasty Versus Endoscopic Urethrotomy (the OPEN Trial)63
Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement62
Reply to Deepansh Dalela, Isaac Palma-Zamora, and Craig Rogers’ Letter to the Editor re: Fredrick Leidberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by t62
0.1615309715271